Literature DB >> 17712822

Biosynthetic pathways of the endocannabinoid anandamide.

Yasuo Okamoto1, Jun Wang, Jun Morishita, Natsuo Ueda.   

Abstract

Anandamide (=N-arachidonoylethanolamine) is the first discovered endocannabinoid, and belongs to the class of bioactive, long-chain N-acylethanolamines (NAEs). In animal tissues, anandamide is principally formed together with other NAEs from glycerophospholipid by two successive enzymatic reactions: 1) N-acylation of phosphatidylethanolamine to generate N-acylphosphatidylethanolamine (NAPE) by Ca2+-dependent N-acyltransferase; 2) release of NAE from NAPE by a phosphodiesterase of the phospholipase D type (NAPE-PLD). Although these anandamide-synthesizing enzymes were poorly understood until recently, our cDNA cloning of NAPE-PLD in 2004 enabled molecular-biological approaches to the enzymes. NAPE-PLD is a member of the metallo-beta-lactamase family, which specifically hydrolyzes NAPE among glycerophospholipids, and appears to be constitutively active. Mutagenesis studies suggested that the enzyme functions through a mechanism similar to those of other members of the family. NAPE-PLD is widely expressed in animal tissues, including various regions in rat brain. Its expression level in the brain is very low at birth, and remarkably increases with development. Analysis of NAPE-PLD-deficient mice and other recent studies revealed the presence of NAPE-PLD-independent pathways for the anandamide formation. Furthermore, calcium-independent N-acyltransferase was discovered and characterized. In this article, we will review recent progress in the studies on these enzymes responsible for the biosynthesis of anandamide and other NAEs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712822     DOI: 10.1002/cbdv.200790155

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN: 1612-1872            Impact factor:   2.408


  46 in total

Review 1.  Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action.

Authors:  Pál Gyombolai; Dorottya Pap; Gábor Turu; Kevin J Catt; György Bagdy; László Hunyady
Journal:  Mol Cell Endocrinol       Date:  2011-11-02       Impact factor: 4.102

2.  Cannabinoid receptor-mediated regulation of neuronal activity and signaling in glomeruli of the main olfactory bulb.

Authors:  Ze-Jun Wang; Liqin Sun; Thomas Heinbockel
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

Review 3.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

Review 4.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 5.  Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.

Authors:  E S Vizi; A Fekete; R Karoly; A Mike
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 6.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

7.  A putative 'pre-nervous' endocannabinoid system in early echinoderm development.

Authors:  G A Buznikov; L A Nikitina; V V Bezuglov; M E Y Francisco; G Boysen; I N Obispo-Peak; R E Peterson; E R Weiss; H Schuel; B R S Temple; A L Morrow; J M Lauder
Journal:  Dev Neurosci       Date:  2009-11-12       Impact factor: 2.984

8.  Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses.

Authors:  Jimok Kim; Bradley E Alger
Journal:  Nat Neurosci       Date:  2010-03-28       Impact factor: 24.884

9.  Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue.

Authors:  Lucia Marquéz; Juan Suárez; Mar Iglesias; Francisco Javier Bermudez-Silva; Fernando Rodríguez de Fonseca; Montserrat Andreu
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

10.  Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis.

Authors:  Gabor Eros; Saleh Ibrahim; Nikolai Siebert; Mihály Boros; Brigitte Vollmar
Journal:  Arthritis Res Ther       Date:  2009-03-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.